Extended Data Table 3 Stratum, irradiated sites, and response for patients on clinical trial

From: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

  1. Response of the local irradiated site (Local) and distant unirradiated sites (Dist) were determined by CT and PET/CT. Percent change from baseline for distant lesions measured by CT are indicated using RECIST and change measured by PET/CT are indicated by PERCIST. The irradiated tumour was not included in RECIST measurements per RECIST guidelines due to radiation-related effects precluding accurate CT measurements (for example, patient ID 1 and 9). NA indicates the value was not measurable based on criteria. Progression of disease due to new lesion(s) before re-imaging (POD New) or due to clinical progression (POD Clin) is also indicated. PD, progression of disease; PR, partial response; SD, stable disease; CMR, complete metabolic response; PMR, partial metabolic response; PMD, progressive metabolic disease. Patient ID 3 is patient PT-102, and patient ID 4 is patient PT-402.
Back to article page